TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: perceived sensitivity of measures to change over time
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immune-related Progression-free Survival (irPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Histological assessability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose (MTD) of ABL001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Probability at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Survival Probability at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Survival Probability at 18 Months
Endpoint domain: Mortality/survival
Primary endpoint: NLRP3 inflammasome activation in fasting white adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Myoglobin plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological aspects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electrophysiological aspects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Kinematics motion analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homocysteine status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endothelial function changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibrinolysis changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inflammation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extracellular vesicles changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Psychiatric Rating Scale (BPRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of MRgFUS of Bone Metastases
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) of RO5185426 From 0 to 8 Hours on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of RO5185426 on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-Life (t1/2) of RO5185426 Following Day 21 Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in the Area of EZ Area of Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatinine decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to remission of clinical-high risk status for psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score on Test of Divided Attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Test on Sustained Selective Attention (TOSSA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants in favor of mammography screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early diagnosis of ventilator-associated pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: conversion rate of memory complaint to dementia
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Responders Based on Fullness/Early Satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gestation of birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mode of birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in circulating miRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between miRNA profile and burden of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to vandetanib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum LDL syndrome biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Triglycerides (TAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Apolipoprotein A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain associated with peripheral intravenous catheterisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-72) for SYR-322Z
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for SYR-322Z
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase Elimination Half-life (T1/2) for SYR-322Z
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment success at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications/adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Days at home within 90 days of surgery
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Physical Activity Minutes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Freedom from reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patient logins to the Outcomes4Me app
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Proven or Probable Invasive Fungal Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Chest X-ray Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Reduction in PASI Score of ≥ 75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Marker Lesion Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: glycosylated hemoglobin (A1C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline for Air Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency, rate and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Frequency of Defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Scar Pliability Measured by Skin Elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Scar Pliability Measured by Skin Induration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of Ziprasidone in agitated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Ziprasidone in agitated patients
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease-related symptoms as measured by change from baseline in FKSI-DRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance (R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA1c from baseline to 26 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose Homogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End Tidal Oxygen Concentration (ETO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Disease Activity Score 28-joint count (DAS28[CRP])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of KIR+CD45+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of FcRg-CD56+CD3- NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical Disease Activity (Seo Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (IBDQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants Adherent to Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Had Surgical Complications Post-Resection
Endpoint domain: Adverse events/effects
Primary endpoint: Completion of psychotherapy sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Local tumor response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in lipid peroxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Daily Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Operative Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete visualisation of papilla duodeni major
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Maximal Active Range of Motion in Knee Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Embryofoetopathy incidence
Endpoint domain: Mortality/survival
Primary endpoint: Congenital abnormality incidence rates
Endpoint domain: Mortality/survival
Primary endpoint: Failure of fracture treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intracranial objective response rate (iORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Genitourinary symptoms of menopause
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypoglycaemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance of viruria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) After 3 Cycles in Part B of the Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Qualification rate of treatment plans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding / Spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity evaluation following CAR19 T-cell administration
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of CAR19 T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volemia variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuromuscular Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet ATP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Differentiation of latent and active TB infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rapid detection of Mtb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Drug sensitivity testing of Mtb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Score on the Montgomery-Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impressions (CGI) scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Seven-day free living physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HMG-CoA reductase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HMG-CoA reductase mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL receptor mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL receptor protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate and Severity of Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in positive and negative emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in depression, anxiety and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in hair cortisol concentration (HCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in area of geographic atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-Month Progression-Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Albuminemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: results of isolated head trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: birth results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: preterm birth results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Decrease in musculoskeletal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum tolerated dose of bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of escalating doses of autologous EBV-specific CTLs
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with a 50% decrease of PVCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and Severity of adverse events (AEs) and IRRs
Endpoint domain: Adverse events/effects
Primary endpoint: Total time of snoring during sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of change in late gadolinium contrast-enhanced area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of complication associated with drug administration method
Endpoint domain: Adverse events/effects
Primary endpoint: Dietary assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of SSc patients correctly identified with pulmonary hypertension severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in WOMAC A1 Subscore at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 5-years overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: whole body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Revascularization Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 months graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain rating using the Wong-Baker scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time it takes for buffered injection to take effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Per Cutaneous Toxicity Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With 20% or Greater Increase in Arm Lymphedema Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Number of Participants With Grade 3 Brachial Plexopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Balance assessment using Biodex Balance System SD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural assessment using Baropedometric Platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot posture assessment using Foot Posture Index (FPI-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal flexibility assessment using Adams forward bending test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean blood flow restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in overall pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Liver indicators of intrapartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver indicators of postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cardio-respiratory phase synchronisation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LF/HF HRV ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: balance recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scapular muscular endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revascularization Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of colorectal cancer patients
Endpoint domain: Mortality/survival
Primary endpoint: Impact on daily function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in bilateral lower limb volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission rate of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of participants with weight loss exceeding 15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of successful evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Subjects With Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hypothyroid status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Number of Hours That Participants Wear the Device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ventilator-free hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mRNA for MxA gene levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total score of Knee Injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Functional subscale score of Knee Injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Plasmatic Interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of patients that become nanoscale artificial nose negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial nerve MEP amplitude ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ecigarette use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Attachment Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health care use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of Acute Success Based on Pre-defined Procedural Endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Arrhythmia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes